PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)

• Sarah A. Holstein,
• Hira Mian,
• Cyrille Touzeau,
• Edwin Kingsley,
• Dan Vogl,
• Richard Zuniga,
• Kaveri Suryanarayan,
• Shining Wang,
• Laura Thesillat-Versmee,
• Yuyin Liu,
• Tian Chen,
• Yefei Zhang,
• Xavier Parot,
• Hans C. Lee

Affiliations

Sarah A. Holstein

1 University of Nebraska Medical Center, Omaha, NE, United States

Hira Mian

2 McMaster University, Hamilton, Ontario, Canada

Cyrille Touzeau

3 Centre Hospitalier Universitaire de Nantes, Nantes, France

Edwin Kingsley

4 Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States

Dan Vogl

5 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States

Richard Zuniga

6 New York Cancer & Blood Specialists, New York, NY, United States

Kaveri Suryanarayan

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Shining Wang

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Laura Thesillat-Versmee

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Yuyin Liu

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Tian Chen

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Yefei Zhang

7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Xavier Parot

8 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States

Hans C. Lee

9 The University of Texas MD Anderson Cancer Center, Houston, TX, United States